RSS-Feed abonnieren
DOI: 10.1055/s-0032-1309275
Die blutzuckersenkende und fettabbauende Aktivität der Bittermelone – Neue Erkenntnisse hinsichtlich der Wirkmechanismen
Verantwortlicher Herausgeber dieser Rubrik:
Publikationsverlauf
Publikationsdatum:
05. November 2012 (online)
![](https://www.thieme-connect.de/media/phyto/201205/lookinside/thumbnails/10.1055-s-0032-1309275-1.jpg)
Zusammenfassung
Zur Bittermelone (Momordica charantia L.) gibt es mehr als 100 wissenschaftliche Publikationen, die einen Effekt bei der Blutzuckerregulation belegen. Eine Wirkung beim metabolischen Syndrom konnte erstmals nachgewiesen werden. Die angegebenen Wirkmechanismen für M. charantia waren bisher vorwiegend hypothetisch. So galt die Aktivierung von Inkretinen (intestinale, endokrine Hormone), die die Insulinfreisetzung stimulieren, als potenzieller Mechanismus oder die Resorptionshemmung von Glukose durch Hemmung von Glukosidasen und Disaccharasen im Intestinaltrakt. Neuerdings haben Wissenschaftler aus Kiel einen weiteren interessanten Interpretationsansatz gefunden. M.-charantia-Extrakt enthält einen spezifischen Hemmstoff der 11 β-Hydroxysteroid-Dehydrogenase Typ 1(11 β-HSD1), ein Enzym, das bei der Pathogenese von Diabetes und Adipositas eine Schlüssel rolle spielt und weltweit Ziel intensiver Forschung ist.
Summary
Improvement of glucose metabolism and weight lowering activity of bitter melon
There are more than 100 scientific publications supporting the blood sugar regulation effect of bitter melon (Momordica charantia L.). For the first time, however, an effect on the metabolic syndrome has been established. Hitherto, the mode of action of M. charantia was predominantly hypothetical. These included the activation of incretins (a group of gastrointestinal, endocrinal hormones) that stimulate an increase in the amount of insulin as potential mechanism or the resorption inhibition of glucose via the inhibition of glucosidases and disaccharases in the intestinal tract. As reported in this article, scientists from Kiel, Germany, have found a further new interesting approach regarding bitter melon. The extract from M. charantia contains a specific inhibitor of 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1), an enzyme that plays a key role in the pathogenesis of diabetes as well as obesity. It is a target candidate for worldwide research.
-
Literatur
- 1 Ahmad N, Hassan MR, Halder H, Benoor KS. Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med Res Counc Bull 1999; 25: 11-13
- 2 Ahmed I, Adeghate E, Sharma AK et al. Effects of Momordica charantia fruit juice on islet morphology in the pancreas of stretozotocin-diabetic rat. Diabetes Res Clin Pract 1998; 40: 145-151
- 3 Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003; 60: 356-359
- 4 Blum A, Favia AD, Maser E. 11 beta-hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds. Mol Cell Endocrinol 2009; 301: 132-136
- 5 Blum A, Loerz C, Martin HJ et al. Momordica charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11 β -hydroxysteroid dehydrogenase type 1 inhibitor. J Steroid Biochem Mol Biol 2012; 128: 51-55
- 6 Boyle CD, Kowalski TJ. 11 β -hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Expert Opin Ther Pat 2009; 19: 801-825
- 7 Chaturvedi P. Antidiabetic potentials of Momordica charantia: multiple mechanisms behind the effects. J Med Food 2012; 15: 101-107
- 8 Chen Q, Chan LL, Li ET. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr 2003; 133: 1088-1093
- 9 Day C, Cartwright T, Provost J, Bailey CJ. Hypoglycaemic effect of Momordica charantia extracts. Planta Med 1990; 56: 426-429
- 10 Dhanesha N, Joharapurkar A, Shah G et al. Inhibition of 11 β -Hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice. Clin Exp Pharmacol Physiol 2012; 39: 69-77
- 11 Harinantenaina L, Tanaka M, Takaoka S et al. Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem Pharm Bull 2006; 54: 1017-1021
- 12 Hauner H, Schmid P, Pfeiffer EF. Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. J Clin Endocrinol Metab 1987; 64: 832-835
- 13 Hauner H, Wabitsch M, Pfeiffer EF. Differentiation of adipocyte precursor cells from obese and nonobese adult women and from different adipose tissue sites. Horm Metabol Res Suppl Series 1988; 19: 35-39
- 14 Iovino A, Scheen A. Modulation of tissue exposure to cortisol, a new perspective for reducing the metabolic risk associated with obesity. Rev Med Liege 2010; 65: 140-146
- 15 Jamieson PM, Walker BR, Chapman KE et al. 11 β -Hydroxysteroid dehydrogenase type 1 is a predominant 11 β -reductase in the intact perfused rat liver. J Endocrinol 2000; 165: 685-692
- 16 Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 1981; 44: 648-655
- 17 Leatherdale BA, Panesar RK, Singh G et al. Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J 1981; 282: 1823-1824
- 18 Liu J, Wang L, Zhang A et al. Adipose tissuetargeted 11 β -hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-in-duced obesity. Endocr J 2011; 58: 199-209
- 19 Lotlikar MM, Rao MR. Pharmacology of a hypoglycemic principle isolated from the fruits of Momordica charantia Linn. Ind J Pharmacy 1966; 28: 129-133
- 20 Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170
- 21 Matsuda H, Li Y, Murakami T et al. Antidiabetic principlesof natural medicines. III. Structure-related inhibitory activity and action modeof oleanolicacid glycosideson hypoglycemic activity. Chem Pharm Bull (Tokyo) 1998; 46: 1399-1403
- 22 Miura T, Itoh C, Iwamoto N et al. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol 2001; 47: 340-344
- 23 Neuwinger HD. Afrikanische Arzneipflanzen und Jagdgifte. 2. Aufl. Stuttgart: Wissenschaftl. Verlagsges.; 1998: 404-406
- 24 Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-1962
- 25 Prinz S, Kopp B. Momordica charantia . Österreichische Apothekerzeitung 2004; 58: 111-113
- 26 Rathi SS, Grover JK, Vats V. The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism. Phytother Res 2002; 16: 236-243
- 27 Rivera G. Preliminary chemical and pharmacological studies on cundeamor, Momordica charantia L.. Americ J Pharm 1942; 114: 72-87
- 28 Senanayake GV, Maruyama M, Shibuya K et al. The effects of bitter melon (Momordica charantia) on serum and liver triglyceride levels in rats. J Ethnopharmacol 2004; 91: 257-262
- 29 Singh S, Tice C. Structure based design of 11 β -HSD1 inhibitors. Curr Pharm Biotechnol 2010; 11: 779-791
- 30 Sreejayan Rao MN. Oxygen free radical scavenging activity of the juice of Momordica charantia fruits. Fitoterapia 1991; 62: 344-346
- 31 Stimson RH, Andersson J, Andrew R et al. Cortisol release from adipose tissue by 11 β -hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009; 58: 46-53
- 32 Tan MJ, Ye JM, Turner N et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPKpathway. Chem Biol 2008; 15: 263-273
- 33 Tomlinson JW, Stewart PM. The functional consequences of 11 β -hydroxysteroid dehydrogenase expression in adipose tissue. Horm Metab Res 2002; 34: 746-751
- 34 Tsai CH, Chen EC, Tsay HS, Huang CJ. Wild bitter gourd improves metabolic syndrome: A preliminary dietary supplementation trial. Nutr J 2012; 11: 4
- 35 Wang M. Inhibitors of 11 β -hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Handb Exp Pharmacol 2011; 203: 127-146
- 36 Wang Z, Wang RM, Owji AA et al. Glucagonlike peptide-1 is a physiological incretin in rat. J Clin Invest 1995; 95: 417-421
- 37 Zänker KS, Gottschalk G, Hans S. Sicherheits- und Wirksamkeitsstudie mit einem Extrakt aus Momordica charantia bei Patienten mit Typ-2-Diabetes. Z Phytother 2003; 24: 163-169
- 38 Zänker KS, Mang B, Wolters M, Hahn A. Personalized diabetes and cancer medicine: A rationale for anti-diabetic nutrition (Bitter Melon) in a supportive setting. Current Cancer Therapy Rev 2012; 8: 66-77